Compare WSE & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSE | ARWR |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 12.4B |
| IPO Year | 2025 | 2009 |
| Metric | WSE | ARWR |
|---|---|---|
| Price | $10.84 | $59.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $16.98 | ★ $107.71 |
| AVG Volume (30 Days) | ★ 2.1M | 1.6M |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $17.78 | N/A |
| Revenue Next Year | $18.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.78 | $37.06 |
| 52 Week High | $13.66 | $95.49 |
| Indicator | WSE | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 33.61 | 38.71 |
| Support Level | N/A | $54.96 |
| Resistance Level | $13.23 | $66.37 |
| Average True Range (ATR) | 0.31 | 2.24 |
| MACD | -0.06 | 0.74 |
| Stochastic Oscillator | 3.97 | 53.29 |
Wise is a currency conversion platform that matches, where possible, offsetting currency transactions across borders to reduce costs. The group focuses primarily on private clients and small and midsize enterprises, but it is building out its platform business aimed at providing its services as a backend solution to banks. By operating local accounts in each jurisdiction Wise sends money to or receives money from, this fintech offers faster and cheaper currency transfer services than incumbents (banks). Wise has started to broaden its product offering, issuing its clients debit cards and allowing customers to invest funds in various asset management products.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.